The	the	O	O	O	O
use	use	O	O	O	O
and	and	O	O	O	O
toxicity	toxicity	O	DISEASE	OTHERS	I
of	of	O	O	O	O
didanosine	didanosine	CHEMICALS	O	OTHERS	I
(	(	O	O	O	O
ddI	ddi	O	O	OTHERS	I
)	)	O	O	O	O
in	in	O	O	O	O
HIV	hiv	O	O	O	O
antibody-positive	antibody-positive	O	O	O	O
individuals	individuals	O	O	O	O
intolerant	intolerant	O	O	O	O
to	to	O	O	O	O
zidovudine	zidovudine	CHEMICALS	O	OTHERS	I
(AZT)One	(azt)one	O	O	O	O
hundred	hundred	O	O	O	O
and	and	O	O	O	O
fifty-one	fifty-one	O	O	O	O
patients	patients	O	O	O	O
intolerant	intolerant	O	O	O	O
to	to	O	O	O	O
zidovudine	zidovudine	CHEMICALS	O	OTHERS	I
(	(	O	O	O	O
AZT	azt	CHEMICALS	O	OTHERS	I
)	)	O	O	O	O
received	received	O	O	O	O
didanosine	didanosine	CHEMICALS	O	OTHERS	I
(	(	O	O	O	O
ddI	ddi	O	O	OTHERS	I
)	)	O	O	O	O
to	to	O	O	O	O
a	a	O	O	O	O
maximum	maximum	O	O	O	O
dose	dose	O	O	O	O
of	of	O	O	O	O
12.5	12.5	O	O	O	O
mg/kg/day	mg/kg/day	O	O	O	O
.	.	O	O	O	O

Patient	patient	O	O	O	O
response	response	O	O	O	O
was	was	O	O	O	O
assessed	assessed	O	O	O	O
using	using	O	O	O	O
changes	changes	O	O	O	O
in	in	O	O	O	O
CD4	cd4	O	O	O	O
+	+	O	O	O	O
lymphocyte	lymphocyte	O	O	O	O
subset	subset	O	O	O	O
count	count	O	O	O	O
,	,	O	O	O	O
HIV	hiv	O	O	O	O
p24	p24	O	O	O	O
antigen	antigen	O	O	O	O
,	,	O	O	O	O
weight	weight	O	O	O	O
,	,	O	O	O	O
and	and	O	O	O	O
quality	quality	O	O	O	O
of	of	O	O	O	O
life	life	O	O	O	O
.	.	O	O	O	O

Seventy	seventy	O	O	O	O
patients	patients	O	O	O	O
developed	developed	O	O	O	O
major	major	O	O	O	O
opportunistic	opportunistic	O	DISEASE	OTHERS	I
infections	infections	O	DISEASE	OTHERS	I
whilst	whilst	O	O	O	O
on	on	O	O	O	O
therapy	therapy	O	O	O	O
;	;	O	O	O	O
this	this	O	O	O	O
was	was	O	O	O	O
the	the	O	O	O	O
first	first	O	O	O	O
AIDS	aids	O	DISEASE	OTHERS	I
diagnosis	diagnosis	O	O	O	O
in	in	O	O	O	O
17	17	O	O	O	O
.	.	O	O	O	O

Only	only	O	O	O	O
minor	minor	O	O	O	O
changes	changes	O	O	O	O
in	in	O	O	O	O
CD4	cd4	O	O	O	O
+	+	O	O	O	O
lymphocyte	lymphocyte	O	O	O	O
subset	subset	O	O	O	O
count	count	O	O	O	O
were	were	O	O	O	O
observed	observed	O	O	O	O
in	in	O	O	O	O
AIDS	aids	O	DISEASE	OTHERS	I
patients	patients	O	O	O	O
,	,	O	O	O	O
although	although	O	O	O	O
a	a	O	O	O	O
more	more	O	O	O	O
significant	significant	O	O	O	O
rise	rise	O	O	O	O
occurred	occurred	O	O	O	O
in	in	O	O	O	O
those	those	O	O	O	O
with	with	O	O	O	O
earlier	earlier	O	O	O	O
stages	stages	O	O	O	O
of	of	O	O	O	O
disease	disease	O	O	O	O
.	.	O	O	O	O

Of	of	O	O	O	O
those	those	O	O	O	O
positive	positive	O	O	O	O
for	for	O	O	O	O
p24	p24	O	O	O	O
antigen	antigen	O	O	O	O
at	at	O	O	O	O
the	the	O	O	O	O
commencement	commencement	O	O	O	O
of	of	O	O	O	O
the	the	O	O	O	O
study	study	O	O	O	O
67	67	O	O	O	O
%	%	O	O	O	O
showed	showed	O	O	O	O
a	a	O	O	O	O
positive	positive	O	O	O	O
response	response	O	O	O	O
,	,	O	O	O	O
and	and	O	O	O	O
this	this	O	O	O	O
was	was	O	O	O	O
most	most	O	O	O	O
likely	likely	O	O	O	O
in	in	O	O	O	O
those	those	O	O	O	O
with	with	O	O	O	O
CD4	cd4	O	O	O	O
+	+	O	O	O	O
lymphocyte	lymphocyte	O	O	O	O
subset	subset	O	O	O	O
counts	counts	O	O	O	O
above	above	O	O	O	O
100	100	O	O	O	O
mm3	mm3	O	O	O	O
.	.	O	O	O	O

A	a	O	O	O	O
positive	positive	O	O	O	O
weight	weight	O	O	O	O
response	response	O	O	O	O
was	was	O	O	O	O
seen	seen	O	O	O	O
in	in	O	O	O	O
16	16	O	O	O	O
%	%	O	O	O	O
of	of	O	O	O	O
patients	patients	O	O	O	O
.	.	O	O	O	O

Most	most	O	O	O	O
patients	patients	O	O	O	O
showed	showed	O	O	O	O
improvement	improvement	O	O	O	O
in	in	O	O	O	O
individual	individual	O	O	O	O
parameters	parameters	O	O	O	O
and	and	O	O	O	O
global	global	O	O	O	O
score	score	O	O	O	O
of	of	O	O	O	O
quality	quality	O	O	O	O
of	of	O	O	O	O
life	life	O	O	O	O
.	.	O	O	O	O

Adverse	adverse	O	O	O	O
reactions	reactions	O	O	O	O
possibly	possibly	O	O	O	O
attributable	attributable	O	O	O	O
to	to	O	O	O	O
didanosine	didanosine	CHEMICALS	O	OTHERS	I
were	were	O	O	O	O
common	common	O	O	O	O
.	.	O	O	O	O

The	the	O	O	O	O
most	most	O	O	O	O
common	common	O	O	O	O
side-effect	side-effect	O	O	O	O
was	was	O	O	O	O
diarrhoea	diarrhoea	O	O	OTHERS	I
,	,	O	O	O	O
which	which	O	O	O	O
resulted	resulted	O	O	O	O
in	in	O	O	O	O
cessation	cessation	O	O	O	O
of	of	O	O	O	O
therapy	therapy	O	O	O	O
in	in	O	O	O	O
19	19	O	O	O	O
individuals	individuals	O	O	O	O
.	.	O	O	O	O

Peripheral	peripheral	O	DISEASE	OTHERS	I
neuropathy	neuropathy	O	DISEASE	OTHERS	I
occurred	occurred	O	O	O	O
in	in	O	O	O	O
12	12	O	O	O	O
patients	patients	O	O	O	O
and	and	O	O	O	O
pancreatitis	pancreatitis	O	O	OTHERS	I
in	in	O	O	O	O
six	six	O	O	O	O
.	.	O	O	O	O

Thirteen	thirteen	O	O	O	O
patients	patients	O	O	O	O
developed	developed	O	O	O	O
a	a	O	O	O	O
raised	raised	O	O	O	O
serum	serum	O	O	O	O
amylase	amylase	O	O	O	O
without	without	O	O	O	O
abdominal	abdominal	O	DISEASE	OTHERS	I
pain	pain	O	DISEASE	OTHERS	I
.	.	O	O	O	O

Seven	seven	O	O	O	O
patients	patients	O	O	O	O
developed	developed	O	O	O	O
glucose	glucose	CHEMICALS	O	OTHERS	I
tolerance	tolerance	O	O	OTHERS	I
curves	curves	O	O	OTHERS	I
characteristic	characteristic	O	O	O	O
of	of	O	O	O	O
diabetes	diabetes	O	DISEASE	OTHERS	I
but	but	O	O	O	O
these	these	O	O	O	O
were	were	O	O	O	O
mild	mild	O	O	O	O
,	,	O	O	O	O
did	did	O	O	O	O
not	not	O	O	O	O
require	require	O	O	O	O
treatment	treatment	O	O	O	O
and	and	O	O	O	O
returned	returned	O	O	O	O
to	to	O	O	O	O
normal	normal	O	O	O	O
on	on	O	O	O	O
ceasing	ceasing	O	O	O	O
didanosine	didanosine	CHEMICALS	O	OTHERS	I
.	.	O	O	O	O

